United Therapeutics (NASDAQ:UTHR) Price Target Lowered to $295.00 at Wells Fargo & Company

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its price objective dropped by investment analysts at Wells Fargo & Company from $314.00 to $295.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an "equal weight" rating on the biotechnology company's stock. Wells Fargo & Company's price target would indicate a potential upside of 6.45% from the stock's current price.

A number of other analysts have also recently commented on the company. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. HC Wainwright set a $400.00 target price on shares of United Therapeutics and gave the company a "buy" rating in a research report on Thursday. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price on the stock. Morgan Stanley dropped their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Finally, UBS Group dropped their target price on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research report on Monday, June 30th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $379.69.

United Therapeutics Stock Down 1.7%

Shares of UTHR stock traded down $4.82 on Thursday, hitting $277.13. The stock had a trading volume of 198,119 shares, compared to its average volume of 492,975. United Therapeutics has a one year low of $266.98 and a one year high of $417.82. The business has a 50 day moving average price of $299.07 and a 200 day moving average price of $314.68. The company has a market cap of $12.50 billion, a PE ratio of 11.09, a P/E/G ratio of 6.49 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same period in the prior year, the firm posted $5.85 EPS. The business's revenue was up 11.7% compared to the same quarter last year. Equities research analysts expect that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity

In other news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $10,297,208.76. The trade was a 23.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the sale, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,681 shares of company stock worth $21,318,359. 10.30% of the stock is owned by insiders.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. LPL Financial LLC lifted its stake in United Therapeutics by 122.8% during the 4th quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company's stock worth $5,024,000 after acquiring an additional 7,847 shares in the last quarter. Orion Portfolio Solutions LLC grew its stake in United Therapeutics by 22.4% during the 4th quarter. Orion Portfolio Solutions LLC now owns 4,021 shares of the biotechnology company's stock worth $1,419,000 after purchasing an additional 735 shares in the last quarter. Allstate Corp acquired a new position in United Therapeutics during the 4th quarter worth $415,000. O Shaughnessy Asset Management LLC grew its stake in United Therapeutics by 6.2% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 3,930 shares of the biotechnology company's stock worth $1,387,000 after purchasing an additional 228 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in United Therapeutics by 31.4% during the 4th quarter. Franklin Resources Inc. now owns 329,379 shares of the biotechnology company's stock worth $116,218,000 after purchasing an additional 78,660 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.